– CANADA, Mississauga – NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today that Karen A. Licitra will be joining the Company’s Board of Directors.
Ms. Licitra has a track record of accomplishments in sales, marketing, commercial and general management in the global healthcare industry. In her career with Johnson & Johnson that spanned over 30 years, she most recently served as Corporate Vice President Worldwide Government Affairs & Policy before retiring in August 2015. Prior to her role in governmental affairs, Ms. Licitra was Worldwide Chairman, Global Medical Solutions Group within Johnson & Johnson’s Medical Device and Diagnostics segment. In that role, she was responsible for setting the strategy and vision for an $8.6 billion global portfolio of healthcare companies including VisionCare, Diabetes Care, Ortho Clinical Diagnostics, and Advanced Sterilization Products, as well as the Sedation business unit. She also led the Medical Device & Diagnostics center of excellence for regulatory affairs. Before her rise to Worldwide Chairman, Ms. Licitra was Company Group Chairman for Johnson & Johnson and Worldwide Franchise Chairman for Ethicon Endo-Surgery, Inc. and Johnson & Johnson Medical, Canada. She is a member of the board of directors of SI-Bone, Inc. and was a member of the Board of Trustees for the Saint Peter’s Healthcare System. Ms. Licitra also served as Chair Emeritus for the Campaign to End Obesity, which advances U.S. national policy and platforms to combat obesity, as well as Chair of the Campaign’s Advisory Council. She was named to Fortune’s 50 Most Powerful Women in Business list in 2012.
“Karen is a seasoned leader who brings an impressive wealth of healthcare knowledge and executive management expertise to NOVADAQ,” commented Bill MacKinnon, Chairman of the Company’s Board of Directors. “We are excited to welcome her to the Board and very much look forward to the valuable expertise and leadership she will bring to Novadaq.”
NOVADAQ further announced that, in conjunction with Ms. Licitra’s appointment, Harold O. Koch will be resigning from his position as a director of the Company and chair of the Governance Committee.
Commenting on Mr. Koch’s thirteen year tenure on the Company’s Board, Mr. MacKinnon added, “Harold has worked tirelessly during his time on the Board of Directors and has provided critical guidance to the Company since its formation and through its critical growth periods. On behalf of the Board of Directors and everyone at the Company, I would like to thank Harold for his dedication to NOVADAQ. We wish Harold the very best in his future endeavours and will greatly miss him.”
About NOVADAQ Technologies Inc.
NOVADAQ’s global mission is to enable physicians with point-of-care imaging solutions that provide real time clinically significant and actionable information to improve care quality and lower healthcare costs. Using NOVADAQ’s SPY fluorescence imaging technology, physicians can personalize therapy and achieve optimal results through the precise visualization of blood flow in vessels, micro-vessels, tissue perfusion and critical anatomical structures during the course of treatment. SPY technology enables the delivery of personalized therapies and the achievement of the optimal results for each individual patient. More than 210 peer-reviewed publications demonstrate that the use of SPY technology will reduce post-procedure complication rates and the cost of care for a broad variety of surgical treatments for cancer, cardiovascular diseases and other conditions, helping to ensure that patients benefit from the very best possible treatment and outcome.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.